Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics.
Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity’s duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 3, 2022 | Series Unknown | — | 1 | In-Q-Tel | — | Detail |
Mar 9, 2022 | Series A | $60M | 19 | At One Ventures Thomas Tull | — | Detail |
May 6, 2021 | Seed | $15M | 17 | Thomas Tull | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
In-Q-Tel | Yes | Series Unknown |
At One Ventures | Yes | Series A |
Thomas Tull | Yes | Series A |
11:11 Media | — | Series A |
Animal Capital | — | Series A |
Animoca Brands | — | Series A |
Bold Capital Partners | — | Series A |
Boost VC | — | Series A |
Breyer Capital | — | Series A |
Builders VC | — | Series A |